文献速递眼底病与葡萄膜炎

缓释地塞米松用于增生性玻璃体视网膜病变:一项前瞻性随机对照临床试验

Slow-Release Dexamethasone in Proliferative Vitreoretinopathy: A Prospective, Randomized Controlled Clinical Trial.
PubMed 文献 · Ophthalmology · 2017-02-23

这项为期2年的单中心前瞻性随机对照试验纳入140例因视网膜脱离伴 established 增生性玻璃体视网膜病变(PVR,C级)需行玻璃体切除联合硅油填充的患者,1:1随机分入标准治疗组或辅以0.7 mg缓释地塞米松植入物(Ozurdex)组。结果显示两组主要解剖成功率相似(49.3% vs 46.3%,OR 0.89,95%CI 0.46-1.74,P=0.733),但6个月时辅药组黄斑囊样水肿和中心凹厚度>300 μm的比例低于对照组。

要点

  • 辅以缓释地塞米松未改善PVR玻璃体切除联合硅油填充眼的主要解剖成功率(49.3% vs 46.3%,P=0.733)。
  • 6个月时辅药组黄斑囊样水肿比例42.7%,低于对照组的67.2%(P=0.004)。
  • 6个月时辅药组中心凹厚度>300 μm比例47.6%,低于对照组的67.7%(P=0.023)。

核心结论

  • 缓释地塞米松植入物未改善因PVR行玻璃体切除联合硅油填充眼的主要解剖成功率。
  • 作者认为需要进一步临床试验以改善这类眼的解剖和视力结局,但本研究表明接受缓释地塞米松治疗的玻璃体切除眼在6个月时黄斑囊样水肿减少更明显。

研究设计与样本

  • 为期2年、单中心、前瞻性、参与者和术者设盲的随机对照临床试验(EudraCT No. 2011-004498-96)。
  • 共140例因视网膜脱离伴 established PVR(C级)需行玻璃体切除联合硅油填充的患者,按1:1随机分入标准治疗(对照)组或研究治疗(辅药)组。
  • 辅药组在玻璃体切除手术时和硅油取出时各注射0.7 mg缓释地塞米松(Ozurdex),对照组接受标准治疗。

主要发现

  • 主要结局评估显示两组解剖成功率相似:辅药组49.3% vs 对照组46.3%(OR 0.89,95%CI 0.46-1.74,P=0.733)。
  • 6个月时平均视力辅药组为38.3个ETDRS字母,对照组为40.2个ETDRS字母。
  • 两组完全/后部视网膜复位率和PVR复发率等次要解剖结局相当。
  • 6个月时辅药组黄斑囊样水肿比例为42.7%,低于对照组的67.2%(P=0.004)。
  • 6个月时辅药组中心凹厚度>300 μm比例为47.6%,低于对照组的67.7%(P=0.023)。

关键数值与推荐

  • 主要结局指标为6个月时无需额外玻璃体视网膜手术干预、取出硅油后视网膜稳定复位的患者比例。
  • 次要结局包括最终视力(中位数及ETDRS 55个字母或更好)、黄斑囊样水肿、中心凹厚度和和黄斑体积、明显PVR复发、完全和后部视网膜复位、牵拉性视网膜脱离、低眼压/眼压升高、黄斑前膜/视网膜前膜、白内障和生活质量。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出需要进一步临床试验以改善这类眼的解剖和视力结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To test the hypothesis that adjunctive slow-release dexamethasone implant (Ozurdex; Allergan Inc, Irvine, CA) can improve the outcomes of vitreoretinal surgery for established proliferative vitreoretinopathy (PVR). DESIGN: A 2-year, single-center, prospective, participant- and surgeon-masked randomized controlled clinical trial (EudraCT No. 2011-004498-96). PARTICIPANTS: A total of 140 patients requiring vitrectomy surgery with silicone oil for retinal detachment with established PVR (Grade C) were randomized to standard (control) or study treatment (adjunct) in a 1:1 allocation ratio. METHODS: Intraoperatively, the adjunct group received an injection of 0.7 mg of slow-release dexamethasone (Ozurdex) at the time of (1) vitrectomy surgery and (2) silicone oil removal. The control group received standard care. MAIN OUTCOME MEASURES: Primary outcome measure was the proportion of patients with a stable retinal reattachment with removal of silicone oil without additional vitreoretinal surgical intervention at 6 months. Secondary outcomes included (1) final visual acuity (VA) (median and Early Treatment Diabetic Retinopathy Study [ETDRS] of 55 letters or better); (2) cystoid macular edema (CMO), foveal thickness, and macular volume; (3) development of overt PVR recurrence; (4) complete and posterior retinal reattachment; (5) tractional retinal detachment; (6) hypotony/increased intraocular pressure (IOP); (7) macula pucker/epiretinal membrane; (8) cataract; and (9) quality of life. RESULTS: All 140 patients were recruited within 25 months of study commencement; 138 patients had primary outcome data. Primary outcome assessment showed similar results in anatomic success between the 2 groups (49.3% vs. 46.3%, adjunct vs. control; odds ratio, 0.89; 95% confidence interval, 0.46-1.74; P = 0.733). Mean VA at 6 months was 38.3 ETDRS letters and 40.2 letters in the adjunct and control groups, respectively. Secondary anatomic outcomes (complete/posterior reattachment rates and PVR recurrence) were comparable between the 2 groups. At 6 months, fewer adjunct patients had CMO (42.7%) or a foveal thickness of >300 μm (47.6%) compared with controls (67.2% and 67.7%, respectively, P = 0.004, P = 0.023). CONCLUSIONS: A slow-release dexamethasone implant did not improve the primary anatomic success rate in eyes undergoing vitrectomy surgery with silicone oil for PVR. Further clinical trials are indicated to improve anatomic and visual outcomes in these eyes, but this study suggests that there is a greater reduction in CMO observed at 6 months in vitrectomized eyes treated with slow-release dexamethasone.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Banerjee PJ, Quartilho A, Bunce C, et al. Slow-Release Dexamethasone in Proliferative Vitreoretinopathy: A Prospective, Randomized Controlled Clinical Trial. Ophthalmology. 2017. PMID: 28237428. doi:10.1016/j.ophtha.2017.01.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。